NEW YORK, NY / ACCESSWIRE / August 8, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Chemours Company (“Chemours” or the “Company”) (CC). Investors who purchased Chemours stock are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/cc.
The investigation concerns whether Chemours and certain of its officers and/or directors have violated federal securities laws.
On August 1, 2019, Chemours disclosed its financial results for the second quarter of 2019. The Company’s earnings missed estimated by a wide margin, and revenues fell 22.5% year-to-year to $1.41 billion, prompting Chemours to cut its full-year earnings guidance. Chemours described the quarter as “challenging on a number of fronts, including softer than expected Ti-Pure demand and the continued impact of illegal imports of HFC refrigerants into Europe.” Following this news, Chemours’s stock price fell $3.47 per share, or 19.11%, to close at $14.69 per share on August 2, 2019.
If you are aware of any facts relating to this investigation, or purchased Chemours shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/cc. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | firstname.lastname@example.org
SOURCE:Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com: